Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nabriva Therapeutics PLC
Nabriva's Antibiotic Lefamulin Does Well In First Of Two Pivotal Trials
Results from the first Phase III study – LEAP 1 – of the antibiotic lefamulin are positive, and Nabriva still has one trial to go. But the firm believes that regardless of that result, the totality of data could be used to support regulatory filings.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice